Regional Analysis
- North America: The U.S. leads with biologics adoption, while Canada focuses on self-injection.
- Europe: Germany, France, and the UK drive demand due to home care trends.
- Asia Pacific: China sees growth from chronic disease prevalence, while Japan emphasizes safety.
- Rest of the World: Brazil expands biologics access, and India boosts vaccine delivery.
Application Analysis
- Hospitals: Expected growth of 4.0%-7.8%, driven by biologics administration. Trends focus on safety devices.
- Mail Order Pharmacies: Projected growth of 3.9%-7.7%, linked to home care. Developments emphasize user-friendliness.
- Ambulatory Surgery Centers: Anticipated growth of 3.8%-7.6%, suited for outpatient care. Advances prioritize precision.
Type Analysis
- Glass: Expected growth of 3.9%-7.7%, valued for stability. Trends highlight durability.
- Plastic: Projected growth of 4.1%-7.9%, key for safety and cost. Advances focus on COP/COC materials.
Key Market Players
Leading firms include ARTE Corporation, offering advanced syringes; SCHOTT AG, investing in production; Credence MedSystems, enhancing safety; Gerresheimer, scaling glass syringes; Vetter Pharma, targeting biologics; Nipro Corporation, boosting precision; and MAEDA INDUSTRY, innovating in polymers.Porter's Five Forces Analysis
- Threat of New Entrants: Moderate, due to high manufacturing and regulatory barriers, though innovative startups can enter.
- Threat of Substitutes: Moderate, as single-chamber syringes compete, but dual chambers offer precision for biologics.
- Bargaining Power of Buyers: Moderate, with hospitals seeking cost-effective, safe syringes, though clinical needs limit options.
- Bargaining Power of Suppliers: Low, with multiple material providers.
- Competitive Rivalry: High, with competition on safety, material innovation, and cost.
Market Opportunities and Challenges
Opportunities:
- Chronic disease prevalence (422 million diabetics) and biologics growth drive demand.
- Home care and lyophilized drugs boost adoption, while safety innovations and Asia’s healthcare expansion enhance usage.
Challenges:
- High production costs limit access in low-income regions.
- Regulatory complexities slow innovation.
- Compatibility issues with biologics restrict expansion.
- Market News
- In March 2024, SCHOTT Pharma invested USD 371 million in a syringe manufacturing facility in North Carolina.
- In January 2023, Sharps Technology planned to launch polymer-based prefilled syringe systems.
- In March 2022, The Dec Group launched the DecFill aseptic filling line for dual-chamber syringes.
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- ARTE Corporation
- SCHOTT AG
- Credence MedSystems
- Gerresheimer
- Vetter Pharma
- Nipro Corporation
- MAEDA INDUSTRY

